Netherlands Heart Journal· 2026Q2· Review
Obesity, incretin-based therapies, and cardiovascular disease in women
- 0citations
- Q2SCImago
- 2026year
Short summary
Incretin-based therapies show promise for obesity treatment in women, demonstrating substantial weight loss and cardiovascular benefits, though sex-specific efficacy and long-term outcomes require further research.
AI-generated from the title and abstract; the full text is not read.
Key points
- Women with obesity face increased risks for heart failure with preserved ejection fraction and ischemia with non-obstructive coronary arteries.
- Incretin-based therapies are emerging as effective pharmacological treatments for obesity, showing substantial weight loss and cardiovascular benefits.
- Sex-specific differences in the efficacy, tolerability, and long-term outcomes of incretin-based therapies in women are not well-researched.
- Reproductive health concerns and access to care are unique considerations for women undergoing obesity treatment.
AI-generated from the title and abstract; the full text is not read.
Abstract
Abstract Obesity in women is a growing and multifaceted public health challenge, driven by complex interactions among biological, hormonal, and psychosocial factors across the life course. From menarche to menopause, hormonal fluctuations influence fat distribution, energy balance, and metabolic risk, contributing to sex-specific trajectories of weight gain. Moreover, women-specific conditions, such as pregnancy-related weight retention, hypertensive disorders of pregnancy, and polyendocrine metabolic ovarian syndrome, further amplify long-term cardiometabolic risk. Women with obesity have an increased risk of heart failure with preserved ejection fraction and ischemia with non-obstructive coronary arteries. Emerging pharmacological treatments for obesity, including incretin-based therapies, offer an evidence-based addition to lifestyle interventions and metabolic and bariatric surgery and have demonstrated substantial weight loss effects and cardiovascular benefits. However, sex-specific differences in efficacy, tolerability, and long-term outcomes of these new pharmacological treatments remain insufficiently researched. Moreover, concerns regarding reproductive health and access to care uniquely affect women. This review addresses the need for a life course and sex-specific approach to obesity and its treatment, integrating metabolic, reproductive, and cardiovascular perspectives.
The authors' abstract, as published at the source. Netherlands Heart Journal, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Obstetrics and Gynecology
Obstetrics and GynecologyMedicine